MedTrace Logo

A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

NCT06954246 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 450

Last updated 2025-06-18

No results posted yet for this study

Summary

This study was designed to compare the efficacy and safety of MHB088C for Injection with treatment of physician's choice (TPC) in participants with relapsed small cell lung cancer (SCLC).

Conditions

  • Small Cell Lung Cancer Extensive Stage

Interventions

DRUG

MHB088C for Injection

2 mg/kg intravenous dose on Day 1 and Day 15 of each 28-day cycle

DRUG

Topotecan

1.25 mg/m\^2 intravenous dose on Day 1 to Day 5 of each 21-day cycle

DRUG

Irinotecan

65 mg/m\^2 intravenous dose on Day 1 and Day 8 of each 21-day cycle

DRUG

Paclitaxel

135 mg/m\^2 intravenous dose on Day 1 of each 21-day cycle

Sponsors & Collaborators

  • Qilu Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-04
Primary Completion
2027-05-31
Completion
2028-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06954246 on ClinicalTrials.gov